Aptamer Group PLC (AIM: APTA), a developer of synthetic binders for the life sciences, announced a significant contract win with a top 3 global pharmaceutical company, sending positive signals to the market.
The news underscores the company's growing presence in the radiopharmaceuticals sector and its potential for future revenue generation. APTA shares are up more than 19% on the news.
The newly signed £360,000 fee-for-service contract focuses on developing Optimer binders for targeted radiopharmaceuticals, potentially applicable in therapeutics.
Aptamer retains the rights for future licensing revenues upon commercialization, creating opportunities for downstream licensing and royalty income.
The move expands Aptamer's technological application into the radiopharmaceuticals market, estimated at $7.5 billion in 2025.
Beyond this major win, Aptamer has secured an additional £665,000 in contract value through recently signed agreements, including £315,000 from smaller deals.
Building on the £1.2 million revenue achieved in FY25, the company has already secured £315,000 in new contracts and project extensions for the current financial year.
The company's financial outlook appears promising, with approximately £1.03 million in contract value visibility for the current period, incorporating £350,000 carried over from FY25.
Aptamer's sales pipeline is said to remain robust, currently at £3.4 million for fee-for-service opportunities. This healthy pipeline suggests sustained commercial momentum.
The additional contracts and extensions include work with a top 5 global pharmaceutical company on an ELISA project, synthesis of an enzyme inhibitor to support a licensing deal, and a therapeutic development agreement with Invizius. These contracts diversify Aptamer's revenue streams across therapeutics, diagnostics, and research sectors.
CEO Dr. Arron Tolley noted, “This significant contract win with a top 3 global pharmaceutical company marks a key expansion of our platform into targeted radiopharmaceuticals and potential therapeutics.”
He added that the company now has two potential therapeutic assets under development, representing a value inflection point.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- Vantage High levels of account and deposit protection – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
